{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:51:31Z","timestamp":1789750291217,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T00:00:00Z","timestamp":1467158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T00:00:00Z","timestamp":1467158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1038\/ja.2016.73","type":"journal-article","created":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T18:02:19Z","timestamp":1467223339000},"page":"600-604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["In vitro susceptibility of \u03b2-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline"],"prefix":"10.1038","volume":"69","author":[{"given":"Yunliang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,29]]},"reference":[{"key":"BFja201673_CR1","unstructured":"Centers for Disease Control and Prevention Antibiotic Resistance Threats in the United States, United States Department of Health and Human Services, Atlanta, GA, USA, (2013)."},{"key":"BFja201673_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1086\/675604","volume":"35","author":"DM Drekonja","year":"2014","unstructured":"Drekonja, D. M. et al. Challenges in the management of infections due to carbapenem-resistant Enterobacteriaceae. Infect. Control Hosp. Epidemiol. 35, 437\u2013439 (2014).","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"BFja201673_CR3","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/cid\/ciu052","volume":"58","author":"MJ Satlin","year":"2014","unstructured":"Satlin, M. J., Jenkins, S. G. & Walsh, T. J. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin. Infect. Dis. 58, 1274\u20131283 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"BFja201673_CR4","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/MCC.0000000000000235","volume":"21","author":"M Bassetti","year":"2015","unstructured":"Bassetti, M. & Righi, E. New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections. Curr. Opin. Crit. Care 21, 402\u2013411 (2015).","journal-title":"Curr. Opin. Crit. Care"},{"key":"BFja201673_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1021\/acsinfecdis.5b00100","volume":"1","author":"K Bush","year":"2015","unstructured":"Bush, K. Investigational agents for the treatment of Gram-negative bacterial infections: a reality check. ACS Infect. Dis. 1, 509\u2013511 (2015).","journal-title":"ACS Infect. Dis."},{"key":"BFja201673_CR6","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2217\/fmb.15.33","volume":"10","author":"AN Amin","year":"2015","unstructured":"Amin, A. N. & Deruelle, D. Healthcare-associated infections, infection control and the potential of new antibiotics in development in the USA. Future Microbiol. 10, 1049\u20131062 (2015).","journal-title":"Future Microbiol."},{"key":"BFja201673_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.coph.2014.09.008","volume":"18","author":"MGP Page","year":"2014","unstructured":"Page, M. G. P. & Bush, K. Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising? Curr. Opin. Pharmacol. 18, 91\u201397 (2014).","journal-title":"Curr. Opin. Pharmacol."},{"key":"BFja201673_CR8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ijantimicag.2015.08.011","volume":"46","author":"K Bush","year":"2015","unstructured":"Bush, K. A resurgence of \u03b2-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Intl. J. Antimicrob. Agents 46, 483\u2013493 (2015).","journal-title":"Intl. J. Antimicrob. Agents"},{"issue":"suppl. 5","key":"BFja201673_CR9","doi-asserted-by":"publisher","first-page":"S397","DOI":"10.1093\/cid\/cir153","volume":"52","author":"Infectious Diseases Society of America","year":"2011","unstructured":"Infectious Diseases Society of Americaet al. Combating antimicrobial resistance: policy recommendations to save lives. Clin. Infect. Dis. 52 (suppl. 5), S397\u2013S428 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"BFja201673_CR10","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1128\/AAC.04809-14","volume":"59","author":"M Abdallah","year":"2015","unstructured":"Abdallah, M. et al. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob. Agents Chemother. 59, 1802\u20131805 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja201673_CR11","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1128\/AAC.01288-13","volume":"57","author":"JA Sutcliffe","year":"2013","unstructured":"Sutcliffe, J. A., O'Brien, W., Fyfe, C. & Grossman, T. H. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob. Agents Chemother. 57, 5548\u20135558 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja201673_CR12","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1128\/AAC.06187-11","volume":"56","author":"TH Grossman","year":"2012","unstructured":"Grossman, T. H. et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob. Agents Chemother. 56, 2559\u20132564 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja201673_CR13","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1128\/AAC.04967-14","volume":"59","author":"TH Grossman","year":"2015","unstructured":"Grossman, T. H., O'Brien, W., Kerstein, K. O. & Sutcliffe, J. A. Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli. Antimicrob. Agents Chemother. 59, 2446\u20132449 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja201673_CR14","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1128\/AAC.04354-14","volume":"59","author":"TH Grossman","year":"2015","unstructured":"Grossman, T. H., Murphy, T. M., Slee, A. M., Lofland, D. & Sutcliffe, J. A. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob. Agents Chemother. 59, 2567\u20132571 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja201673_CR15","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1128\/AAC.01614-13","volume":"58","author":"JS Solomkin","year":"2014","unstructured":"Solomkin, J. S. et al. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob. Agents Chemother. 58, 1847\u20131854 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja201673_CR16","volume-title":"55th Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"DM Livermore","year":"2015","unstructured":"Livermore, D. M., Mushtaq, S., Warner, M. & Woodford, N. Activity of eravacycline against carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii. Abstract F-769. in 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, (2015)."},{"key":"BFja201673_CR17","volume-title":"55th Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"GG Zhanel","year":"2015","unstructured":"Zhanel, G. G. et alActivity of eravacycline and comparators against 3,174 pathogens isolated from Canadian hospitals: CANWARD 2014. Abstract F-771. in 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, (2015)."},{"key":"BFja201673_CR18","volume-title":"53rd Conf. Antimicrobial Agents and Chemotherapy","author":"GA Denys","year":"2013","unstructured":"Denys, G. A. et alChanging epidemiology and molecular characterization of carbapenem-resistant Enterobacteriaceae (CRE) in Indiana Health Care Centers (HCCs) over a 3-year period. Abstract # C2-1445. in: 53rd Conf. Antimicrobial Agents and Chemotherapy, Denver, CO, USA, (2013)."},{"key":"BFja201673_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2012.08.008","volume":"41","author":"K Bush","year":"2013","unstructured":"Bush, K. et al. Detection systems for carbapenemase gene identification should include the SME serine carbapenemase. Intl. J. Antimicrob. Agents 41, 1\u20134 (2013).","journal-title":"Intl. J. Antimicrob. Agents"},{"key":"BFja201673_CR20","volume-title":"54th Interscience Conference on Antimicrobial Agents & Chemotherapy","author":"M Dunn","year":"2014","unstructured":"Dunn, M. et alKPC-2 and VIM carbapenemases decreased in carbapenem-resistant Enterobacteriaceae in Indiana health care centers from 2009 to 2013. in 54th Interscience Conference on Antimicrobial Agents & Chemotherapy, Washington, DC, USA, (2014)."},{"key":"BFja201673_CR21","volume-title":"55th Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"A Kashikar","year":"2015","unstructured":"Kashikar, A. et alOccurrence of VIM and NDM carbapenemases in Indiana health care centers from 2009 to 2013. Abstract C-1095. in 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, (2015)."},{"key":"BFja201673_CR22","unstructured":"CLSI Performance Standards for Antimicrobial Susceptibility Testing. CLSI supplement M100S, 26th edn (Clinical and Laboratory Standards Institute, Wayne, PA, (2016)."},{"key":"BFja201673_CR23","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3201\/eid1809.120355","volume":"18","author":"P Nordmann","year":"2012","unstructured":"Nordmann, P., Poirel, L. & Dortet, L. Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 18, 1503\u20131507 (2012).","journal-title":"Emerg. Infect. Dis."},{"key":"BFja201673_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.diagmicrobio.2011.06.007","volume":"71","author":"MR Fairfax","year":"2011","unstructured":"Fairfax, M. R. et al. Detection of 2 SME-1 carbapenemase-producing Serratia marcescens in Detroit. Diagn. Microbiol. Infect. Dis. 71, 325\u2013326 (2011).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"BFja201673_CR25","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1128\/AAC.44.11.3035-3039.2000","volume":"44","author":"AM Queenan","year":"2000","unstructured":"Queenan, A. M. et al. SME-type carbapenem-hydrolyzing class A \u03b2-lactamases from geographically diverse Serratia marcescens strains. Antimicrob. Agents Chemother. 44, 3035\u20133039 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja201673_CR26","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1128\/AAC.45.4.1151-1161.2001","volume":"45","author":"H Yigit","year":"2001","unstructured":"Yigit, H. et al. Novel carbapenem-hydrolyzing \u03b2-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45, 1151\u20131161 (2001).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja201673_CR27","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1128\/AAC.49.8.3538-3540.2005","volume":"49","author":"K Lolans","year":"2005","unstructured":"Lolans, K., Queenan, A. M., Bush, K., Sahud, A. & Quinn, J. P. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-\u03b2-lactamase (VIM-2) in the United States. Antimicrob. Agents Chemother. 49, 3538\u20133540 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja201673_CR28","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1128\/AAC.00363-06","volume":"50","author":"AM Queenan","year":"2006","unstructured":"Queenan, A. M. et al. SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing \u03b2-lactamases. Antimicrob. Agents Chemother. 50, 3485\u20133487 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja201673_CR29","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1128\/AAC.00533-09","volume":"53","author":"H Sidjabat","year":"2009","unstructured":"Sidjabat, H. et al. Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob Agents Chemother. 53, 4733\u20134739 (2009).","journal-title":"Antimicrob Agents Chemother."},{"key":"BFja201673_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","volume":"70","author":"L Poirel","year":"2011","unstructured":"Poirel, L., Walsh, T. R., Cuvillier, V. & Nordmann, P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn. Microbiol. Infect. Dis. 70, 119\u2013123 (2011).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"BFja201673_CR31","unstructured":"CLSI M07-A9: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. 9th edn (Clinical and Laboratory Standards Institute, Wayne, PA, (2013)."},{"key":"BFja201673_CR32","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1128\/AAC.02403-15","volume":"60","author":"JR Johnson","year":"2015","unstructured":"Johnson, J. R., Porter, S. B., Johnston, B. D. & Thuras, P. Activity of eravacycline against Escherichia coli clinical isolates collected from U.S. veterans in 2011 in relation to coresistance phenotype and sequence type 131 genotype. Antimicrob. Agents Chemother 60, 1888\u20131891 (2015).","journal-title":"Antimicrob. Agents Chemother"},{"key":"BFja201673_CR33","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1128\/AAC.01896-13","volume":"58","author":"M Castanheira","year":"2014","unstructured":"Castanheira, M., Farrell, S. E., Krause, K. M., Jones, R. N. & Sader, H. S. Contemporary diversity of \u03b2-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent \u03b2-lactamase groups. Antimicrob Agents Chemother. 58, 833\u2013838 (2014).","journal-title":"Antimicrob Agents Chemother."},{"key":"BFja201673_CR34","first-page":"1051","volume":"62","author":"Centers for Disease Control & Prevention","year":"2014","unstructured":"Centers for Disease Control & Prevention Notes from the field: New Delhi metallo-\u03b2-lactamase-producing Escherichia coli associated with endoscopic retrograde cholangiopancreatography - Illinois, 2013. Morbid. Mortal. Week Rep. 62, 1051 (2014).","journal-title":"Morbid. Mortal. Week Rep."},{"key":"BFja201673_CR35","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1128\/AAC.04191-14","volume":"59","author":"H Li","year":"2015","unstructured":"Li, H. et al. In vitro susceptibility of characterized \u03b2-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother. 59, 1789\u20131793 (2015).","journal-title":"Antimicrob Agents Chemother."}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ja201673.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ja201673","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ja201673.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:23:49Z","timestamp":1684430629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ja201673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,29]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["BFja201673"],"URL":"https:\/\/doi.org\/10.1038\/ja.2016.73","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,29]]},"assertion":[{"value":"18 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}